AzTrials
AzTrials

Leukemia, Acute Lymphocytic (ALL)Phase 2NCT00566696

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

A Phase 2 study testing CliniMACS, Stem cell transplantation and Fludarabine in people with Leukemia, Acute Lymphocytic (ALL) and Leukemia, Myeloid, Acute(AML), run by St. Jude Children's Research Hospital at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Blood and marrow stem cell transplant has improved the outcome for patients with high-risk hematologic malignancies. However, most patients do not have an appropriate HLA (immune type) matched sibling donor available and/or are unable to identify an acceptable unrelated HLA matched donor through the registries in a… Read more about this study

Who is it for?
Ages Up to 21 years
What is being tested?
CliniMACS, Stem cell transplantation and Fludarabine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
73 participants
Where
1 siteUnited States
Study dates
14 Dec 2007to 6 Feb 2020
Phase
Phase 2

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 21 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Patients less than or equal to 21 years of age; may be greater than 21 years old if a current St. Jude patient or previously treated St. Jude patient within 3 years of completion of prior treatment.
  • Must have one of the following diagnosis:
  • ALL high risk in second remission. Examples include relapse on therapy, first remission duration of less than or equal to 30 months, or relapse within 12 months of completing therapy.
  • ALL in third or subsequent remission.
  • ALL high risk in first remission. Examples include: induction failure, minimal residual disease greater than or equal to 1% marrow blasts by morphology after induction, persistent or recurrent cytogenetic or molecular evidence of disease during therapy requiring additional therapy after induction to achieve remission.
  • High-risk AML in first remission. Examples include monosomy 7, M6, M7, t(6;9), FLT3-ITD, or patients who have greater than or equal to 25% blasts by morphology after induction or who do not achieve CR after 2 courses of therapy (includes myeloid sarcoma).
Show all 37Show fewer
  • Relapsed or persistent AML (less than or equal to 25% blasts in marrow by morphology).
  • AML in second or subsequent morphologic remission (includes myeloid sarcoma).
  • CML in first chronic phase with detectable molecular or cytogenetic evidence of disease despite medical therapy; or CML with a history of accelerated or blast crisis, now in chronic phase; or unable to tolerate tyrosine kinase inhibitor therapy.
  • Juvenile myelomonocytic leukemia (JMML).
  • Myelodysplastic syndrome (MDS).
  • Therapy related (secondary) AML, ALL, or MDS.
  • Hodgkin lymphoma after failure of prior autologous HSCT or unsuitable for autologous HSCT.
  • Non-Hodgkin lymphoma (NHL) in second complete remission (CR2) or subsequent.
  • Has not received a prior allogeneic hematopoietic stem cell transplant.
  • Does not have a suitable HLA-matched sibling donor available for stem cell donation.
  • Does not have a suitable cord blood product or volunteer matched unrelated donor (MUD) available in the necessary time for stem cell donation.
  • Has a suitable HLA partially matched family member available for stem cell donation.
  • Cardiac shortening fraction greater than or equal to 25%.
  • Creatinine clearance or glomerular filtration rate (GFR) greater than or equal to 40 ml/min/1.73 m^2.
  • Forced vital capacity (FVC) greater than or equal to 40% of predicted value or a pulse oximetry value of greater than or equal to 92% on room air.
  • Direct bilirubin less than or equal to 3 mg/dl.
  • Age-dependent performance score of greater than or equal to 50.
  • Serum glutamic pyruvic transaminase (SGPT) less than 3 times the upper limit of normal for age.
  • Karnofsky or Lansky (age-dependent) performance score of greater than or equal to 50.
  • No known allergy to murine products or human anti-mouse antibody (HAMA) results within normal limits.
  • Not pregnant (confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment).
  • Not breast feeding.
  • Partially HLA matched family member.
  • At least 18 years of age.
  • Human immunodeficiency virus (HIV) negative.
  • Not pregnant (confirmed by negative serum or urine pregnancy test within 7 days prior to enrollment).
  • Not breast feeding.
  • Has experienced one of the following disorders post-transplant:
  • graft failure
  • graft rejection
  • delayed hematopoietic and/or immune reconstitution.

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105

Other trials in United States

About this study

Official title: A Reduced Intensity Conditioning Regimen With CD3-Depleted Hematopoietic Stem Cells to Improve Survival for Patients With Hematologic Malignancies Undergoing Haploidentical Stem Cell Transplantation

Blood and marrow stem cell transplant has improved the outcome for patients with high-risk hematologic malignancies. However, most patients do not have an appropriate HLA (immune type) matched sibling donor available and/or are unable to identify an acceptable unrelated HLA matched donor through the registries in a timely manner. Another option is haploidentical transplant using a partially matched family member donor.

Although haploidentical transplant has proven curative in many patients, this procedure has been hindered by significant complications, primarily regimen-related toxicity including GVHD and infection due to delayed immune reconstitution. These can, in part, be due to certain white blood cells in the graft called T cells. GVHD happens when the donor T cells recognize the body tissues of the patient (the host) are different and attack these cells. Although too many T cells increase the possibility of GVHD, too few may cause the recipient's immune system to reconstitute slowly or the graft to fail to grow, leaving the patient at high-risk for significant infection.

Read more

For these reasons, a primary focus for researchers is to engineer the graft to provide a T cell dose that will reduce the risk for GVHD, yet provide a sufficient number of cells to facilitate immune reconstitution and graft integrity. Building on prior institutional trials, this study will provide patients with a haploidentical (HAPLO) graft engineered to specific T cell target values using the CliniMACS system. A reduced intensity, preparative regimen will be used in an effort to reduce regimen-related toxicity and mortality.

The primary aim of the study is to help improve overall survival with haploidentical stem cell transplant in this high risk patient population by 1) limiting the complication of graft versus host disease (GVHD), 2) enhancing post-transplant immune reconstitution, and 3) reducing non-relapse mortality.

Read the detailed description

This study will explore the following objectives:

  1. To assess if the event-free survival at one-year post-transplant for research participants with high-risk hematologic malignancies can be improved following HAPLO hematopoietic stem cell transplant (HSCT) using a graft depleted of CD3+ cells ex vivo and a reduced intensity-conditioning regimen.

Secondary objectives:

  1. To estimate the one-year overall survival (OS) and disease-free survival (DFS) for research participants who receive this study treatment.
  2. To estimate the cumulative incidence of relapse for research participants who receive this study treatment.
  3. To estimate the rate of overall grade III-IV acute GVHD, and the rate and severity of chronic GVHD in research participants.
  4. To estimate the incidence of non-hematologic regimen-related toxicity and regimen-related mortality in the first 100 days post-transplant.

Exploratory objectives:

  1. To explore the biologic significance of soluble interleukin-2 receptor and immunologic state [quantitative lymphocyte studies, V beta spectratyping, T-cell receptor excision circles (TREC) assay] to predict the development of acute and chronic GVHD in these research participants.
  2. To measure the pharmacokinetics of Campath-1H in pediatric HAPLO HSCT recipients

NOTE: This protocol originally used muromonab (OKT3) in the conditioning regimen to prepare participants for haploidentical HCT. After muromonab became unavailable from the manufacturer in 2010, muromonab was replaced by alemtuzumab (Campath-1H) for use in subsequent participants.

Being tested
CliniMACS, Stem cell transplantation, Fludarabine, Thioplex®, L-phenylalanine mustard
Keywords
Haploidentical stem cell transplant, Allogeneic stem cell transplant, Mismatched family member stem cell donor transplant, Bone marrow transplant, High risk hematologic malignancies, T cell depletion methodology, Miltenyi Biotec CliniMACS stem cell selection device, Campath-1H intravenous
Medical subject headings
Leukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Juvenile, Hemoglobinuria, Hemoglobinuria, Paroxysmal, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CliniMACSDevice

    Miltenyi Biotec CliniMACS stem cell selection device

  • Stem cell transplantationProcedure or surgery

    An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.

  • FludarabineDrug

    Also called Fludara

    Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.

  • Thioplex®Drug

    Also called Thiotepa, TESPA, TSPA

    Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.

  • L-phenylalanine mustardDrug

    Also called Melphalan, Phenylalanine mustard, L-PAM, L-sarcolysin

    Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.

  • Mycophenolate mofetilDrug

    Also called MMF, CellCept®

    Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.

  • Rituxan™Drug

    Also called Rituximab

    Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.

  • AlemtuzumabDrug

    Also called Campath-1H, Campath®

    After January 2010, due to the unavailability of muromonab, transplant recipients received a conditioning regimen consisting of systemic chemotherapy and antibodies, including alemtuzumab.

  • CyclophosphamideDrug

    Also called Cytoxan

    Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.

  • Anti-thymocyte globulin (Rabbit)Drug

    Also called Thymoglobulin®, Rabbit ATG

    Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.

  • G-CSFDrug

    Also called Filgrastim, Neupogen®

    Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.

  • MuromonabDrug

    Also called OKT3, Muromonab-CD3

    Prior to January 2010, transplant participants received a conditioning regimen consisting of systemic chemotherapy and antibodies, including muromonab. Muromonab became unavailable from the manufacturer at that time and was replaced by alemtuzumab.

Study groups in NCT00566696
Study groupRoleWhat they receive
High-Risk Hematologic MalignanciesExperimentalParticipants meeting eligibility criteria undergo haploidentical stem cell transplantation along with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (after January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF. Grafts from suitable haploidentical donors are processed using the CliniMACS system.
Receives: Device: CliniMACS; Procedure: Stem cell transplantation; Drug: Fludarabine; Drug: Thioplex®; Drug: L-phenylalanine mustard; Drug: Mycophenolate mofetil; Drug: Rituxan™; Drug: Alemtuzumab; Drug: Cyclophosphamide; Drug: Anti-thymocyte globulin (Rabbit); Drug: G-CSF; Drug: Muromonab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Event-free Survival (EFS)

    To determine if one year event-free survival can be improved in pediatric patients undergoing a haploidentical transplant by using a reduced intensity conditioning regimen and a targeted dose T cell depleted donor product. EFS is defined as time from transplantation to the occurrence of relapse or death due to any cause. Patients who are alive at the time of analysis will be censored. The estimated percentage of participants with EFS at one-year post-transplantation is reported using Kaplan-Meier analysis.

    Measured: one year post-transplant

Secondary outcomes (6)

  1. Overall Survival (OS)

    Estimate the one-year overall survival (OS) for research participants who receive this study treatment. OS is defined as time from transplantation to death due to any cause. Patient who are alive at the time of analysis will be censored. The estimated percentage of participants with OS at one-year post-transplantation is reported using Kaplan-Meier analysis.

    Measured: one year post-transplant

  2. Disease-Free Survival (DFS)

    Estimate the one-year disease-free survival (DFS) for research participants who receive this study treatment. DFS is defined as time from transplantation to the occurrence of relapse or death due to relapse. Patients who are alive at the time of analysis or die due to other causes will be censored at the time of their events. The estimated percentage of participants with DFS at one-year post-transplantation is reported using Kaplan-Meier analysis.

    Measured: One year post-transplant

  3. Incidence of Non-hematologic Regimen-related Toxicities

    Estimate of the incidence of non-hematologic regimen-related toxicity and regimen-related toxicity in the first 100 days post-transplant. The percentage of participants are reported by maximum grade seen using binomial distribution. Participants were graded for toxicity using Common Terminology Criteria for Adverse Events version 3.0. In general, Grade 1 is mild, 2 is moderate toxicity but generally does not require treatment, 3 is severe enough to require treatment, 4 is life-threatening, and 5 means it was associated with death.

    Measured: 100 days post-transplant

  4. Incidence of Regimen-related Mortality

    The incidence of regimen-related mortality in the first 100 days post-transplant is estimated based on binomial distribution.

    Measured: 100 days post-transplant

  5. To Estimate the Cumulative Incidence of Relapse for Research Participants Who Receive This Study Treatment.

    The Cumulative Incidence of Relapse will be reported as the proportion of number of relapses since transplant to the total number of patients at risk at five years post-transplant.

    Measured: five years post-transplant

  6. To Estimate the Rate of Overall Grade III-IV Acute GVHD, and the Rate and Severity of Chronic GVHD in Research Participants.

    The rate of Overall Grade III-IV Acute AVHD will be report as the proportion of patients who have Grade III-IV Acute GVHD to the total patients with transplant. The rate of Chronic GVHD will be report as the proportion of patients who have Chronic GVHD to the total patients with transplant. The Severity of Chronic GVHD will be reported using CTCAE grading system, as a number.

    Measured: five years post-transplant

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Dec 2007 (estimated)
  2. Study start14 Dec 2007
  3. Primary completion27 Jan 2016
  4. Study completion6 Feb 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
73 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00566696
Sponsor's protocol ID
HIFLEX
Other IDs
NCI-2011-03670
Status last verified
Oct 2019
First submitted
29 Nov 2007
Last updated
14 Apr 2020
Data monitoring committee
Yes

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in